Influence of <i>CYP2C19</i> loss-of-function variants on the metabolism of clopidogrel in patients from north-western China

Abstract

Polymorphism of CYP2C19 was significantly associated with plasma concentration ratios of clopidogrel to its inactive metabolite SR26334. Clopidogrel metabolism was regulated by CYP2C19. The *2 and *3 allele carriage were independently associated with the antiplatelet effect of chronic clopidogrel therapy.